Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

European Journal of Cancer

Volumn 50, Issue 6, 2014, Pages 1137-1147

  Blay, Jean Yves ^a   Leahy, Michael G ^b   Nguyen, Binh Bui ^c   Patel, Shreyaskumar R ^d   Hohenberger, Peter ^e   Santoro, Armando ^f   Staddon, Arthur P ^g   Penel, Nicolas ^h   Piperno Neumann, Sophie ⁱ   Hendifar, Andrew ^j   Lardelli, Pilar ^k   Nieto, Antonio ^k   Alfaro, Vicente ^k   Chawla, Sant P ^j  

^a CENTRE LÉON BÉRARD   (France)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c INSTITUT BERGONIÉ   (France)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g PENNSYLVANIA HOSPITAL   (United States)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ INSTITUT CURIE   (France)

^j Sarcoma Oncology Center   (United States)

^k PHARMAMAR S A   (Spain)

more..

Author keywords

Chemotherapy; Sarcomas; Trabectedin; Translocation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; TRABECTEDIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SARCOMA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; YOUNG ADULT;

CHEMOTHERAPY; SARCOMAS; TRABECTEDIN; TRANSLOCATION;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; SARCOMA; TETRAHYDROISOQUINOLINES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897074467     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.01.012     Document Type: Article

References (29)

1. R. Garcia-Carbonero, J.G. Supko, and J. Manola et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22 8 2004 1480 1490
2. A. Yovine, M. Riofrio, and J.Y. Blay et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J Clin Oncol 22 5 2004 890 899
3. A. Le Cesne, J.Y. Blay, and I. Judson et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol 23 3 2005 576 584
4. G.D. Demetri, S.P. Chawla, and M. von Mehren et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol 27 25 2009 4188 4196
5. F. Grosso, R.L. Jones, and G.D. Demetri et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Lancet Oncol 8 7 2007 595 602
6. A. Gronchi, B.N. Bui, and S. Bonvalot et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma Ann Oncol 2011 10.1093/annonc/mdr265
7. A. Le Cesne, S. Cresta, and R.G. Maki et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas Eur J Cancer 48 16 2012 3036 3044
8. C. Turc-Carel, J. Limon, and P. Dal Cin et al. Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas Cancer Genet Cytogenet 23 4 1986 291 299
9. N. Riggi, L. Cironi, and P. Provero et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma Cancer Res 66 14 2006 7016 7023
10. C. Forni, M. Minuzzo, and E. Virdis et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors Mol Cancer Ther 8 2 2009 449 457
11. D. Pink, J. Bertz-Lepel, C. Busemann, U. Bitz, and P. Reichardt Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma Onkologie 35 5 2012 249 252
12. F. Grosso, P. Dileo, and R. Sanfilippo et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma Eur J Cancer 42 10 2006 1484 1490
13. Sanfilippo R, Dileo P, Blay JY, et al. Trabectedin (T) in Advanced, Pre-treated Synovial Sarcoma (SS): A Retrospective Analysis of 61 patients from four European Institutions and from the Italian Rare Cancer Network. In: CTOS Connective Tissue Oncology Society, 17th Annual Meeting. Prague, Czech Republic; 2012. p. Poster #107.
14. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1 1981 207 214
15. H. Choi, C. Charnsangavej, and S.C. Faria et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 13 2007 1753 1759
16. J. Verweij, S.M. Lee, and W. Ruka et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol 18 10 2000 2081 2086
17. S. Stacchiotti, P. Verderio, and A. Messina et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy Cancer 118 23 2012 5857 5866
18. D. Katz, P. Boonsirikamchai, and H. Choi et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma Clin Sarcoma Res 2 1 2012 2
19. A. Le Cesne, A. Yovine, and J.Y. Blay et al. A retrospective pooled analysis of trabectedin safety in 1132 patients with solid tumors treated in phase II clinical trials Invest New Drugs 30 3 2012 1193 1202
20. S. Sleijfer, C. Seynaeve, and J. Verweij Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care Oncologist 10 10 2005 833 841
21. M.L. Keohan, and R.N. Taub Chemotherapy for advanced sarcoma: therapeutic decisions and modalities Semin Oncol 24 5 1997 572 579
22. K. O'Byrne, and W.P. Steward The role of chemotherapy in the treatment of adult soft tissue sarcomas Oncology 56 1 1999 13 23
23. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2 2004 185 229
24. I. Judson, J.A. Radford, and M. Harris et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 37 7 2001 870 877
25. A. Santoro, T. Tursz, and H. Mouridsen et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol 13 7 1995 1537 1545
26. C. Lebedinsky, J. Gomez, and Y.C. Park et al. Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis Cancer Chemother Pharmacol 68 5 2011 1223 1231
27. A.T. van Oosterom, H.T. Mouridsen, and O.S. Nielsen et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients Eur J Cancer 38 18 2002 2397 2406
28. A. Le Cesne, I. Judson, and D. Crowther et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group J Clin Oncol 18 14 2000 2676 2684
29. 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma J Clin Oncol 23 1 2005 105 112